Erschienen in:
18.11.2016 | Editorial
Paediatric cardiopulmonary bypass surgery: the challenges of heterogeneity and identifying a meaningful endpoint for clinical trials
verfasst von:
V. J. Pappachan, K. L. Brown, S. M. Tibby
Erschienen in:
Intensive Care Medicine
|
Ausgabe 1/2017
Einloggen, um Zugang zu erhalten
Excerpt
Survival following paediatric surgery for congenital heart disease (CHD) has improved dramatically over the past two decades; 30-day mortality estimates are now 2.5–4% [
1]. However short- and long-term morbidity remain significant issues and hospital length of stay remains unchanged [
1]. Both are costly and are linked to poorer long-term neurodevelopmental outcomes [
2]. We are now operating on a greater proportion of younger, smaller patients; many with associated extra-cardiac anomalies and chromosomal disorders [
3]. Ideally trials should report both immediate perioperative and post-discharge outcomes [
4]. …